POINT Biopharma Global Overview
Valuation check: PNT's P/E ratio is 12.02, below the Healthcare sector average of 27.42.
Get informed when a big investor buys or sells
+ Follow12.02
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, PNT shows a P/E ratio of 12.02. That is below the Healthcare sector average of 27.42. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 27.42. POINT Biopharma Global is at 12.02, which is lower that average. That is roughly 56.2% below the sector mean. Use the comparison chart on this page to see how PNT stacks up against individual peers as well.
Investors watch PNT's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. POINT Biopharma Global's latest reading is 12.02. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has POINT Biopharma Global's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 12.02) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 27.42, while PNT is at 12.02. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
